Logo
x

Search

Subscribe Now

Esophageal Squamous

BMS' Opdivo (nivolumab) Receives the US FDA's Approval for Advanced Esophageal Squamous Cell Carcinoma

BMS' Opdivo (nivolumab) Receives the US FDA's Approval for Advanced Esophageal Squamous Cell Carcinoma

  • June 11, 2020
Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in P-II ORIENT-2 Study as 2L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in P-II ORIENT-2 Study as 2L Treatment for Advanced or Metastatic Esop...

  • May 14, 2020
BeiGene’s Evimbra (tislelizumab) Receives EC’s Approval for Unresectable, Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

    BeiGene’s Evimbra (tislelizumab) Receives EC’s Approval for Unresectable, Locally Advanced or Metastatic Esophageal Squamous Cell...

    • September 19, 2023
    BeiGene Receives EMA’s CHMP Positive Opinion Recommending Approval of Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

      BeiGene Receives EMA’s CHMP Positive Opinion Recommending Approval of Tislelizumab for Advanced or Metastatic Esophageal Squamous...

      • July 21, 2023
      Henlius Presents P-II Clinical Trial (HLX07-ESCC201) Results of HLX07 for the Treatment of Esophageal Squamous Cell Carcinoma at ASCO 2023

        Henlius Presents P-II Clinical Trial (HLX07-ESCC201) Results of HLX07 for the Treatment of Esophageal Squamous Cell Carcinoma at A...

        • June 8, 2023
        Innovent Presents Final Analysis P-III Study (ORIENT-15) Results of Sintilimab as 1L Treatment of Esophageal Squamous Cell Carcinoma at AACR 2023

          Innovent Presents Final Analysis P-III Study (ORIENT-15) Results of Sintilimab as 1L Treatment of Esophageal Squamous Cell Carcino...

          • April 17, 2023
          Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Cell Carcinoma in South Korea

            Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Ce...

            • March 23, 2023
            CStone Reports P-III Study (GEMSTONE-304) Results of Sugelimab as 1L Treatment of Esophageal Squamous Cell Carcinoma

              CStone Reports P-III Study (GEMSTONE-304) Results of Sugelimab as 1L Treatment of Esophageal Squamous Cell Carcinoma

              • January 3, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.